Evidence map›Paper›PMID 27211564›Full record

ArticleEBioMedicine2016

Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency.

Mikael Ebbo, Laurence Gérard, Sabrina Carpentier, Frédéric Vély, Sophie Cypowyj, Catherine Farnarier, Nicolas Vince, Marion Malphettes, Claire Fieschi, Eric Oksenhendler and 3 more

Abstract readMulticenter Study
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Mikael EbboCentre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, 13288 Marseille, France; Inserm U1104, 13288 Marseille, France; CNRS UMR7280, 13288 Marseille, France; Médecine Interne, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Aix-Marseille University, 13005 Marseille, France.
Laurence GérardImmunopathologie Clinique, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France; EA3518, University Paris 7 Denis Diderot, Paris, France.
Sabrina CarpentierMI-mAbs Consortium (Aix Marseille University), CIML, 13288 Marseille, France.
Frédéric VélyCentre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, 13288 Marseille, France; Inserm U1104, 13288 Marseille, France; CNRS UMR7280, 13288 Marseille, France; Immunologie, Hôpital de la Conception, Assistance Publique -Hôpitaux de Marseille, 13385 Marseille, France.
Sophie CypowyjCentre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, 13288 Marseille, France; Inserm U1104, 13288 Marseille, France; CNRS UMR7280, 13288 Marseille, France.
Catherine FarnarierImmunologie, Hôpital de la Conception, Assistance Publique -Hôpitaux de Marseille, 13385 Marseille, France.
Nicolas VinceInserm U1126, University Paris 7 Denis Diderot, Paris, France.
Marion MalphettesImmunopathologie Clinique, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France; Inserm U1126, University Paris 7 Denis Diderot, Paris, France.
Claire FieschiImmunopathologie Clinique, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France; Inserm U1126, University Paris 7 Denis Diderot, Paris, France.
Eric OksenhendlerImmunopathologie Clinique, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France.
Nicolas SchleinitzCentre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, 13288 Marseille, France; Inserm U1104, 13288 Marseille, France; CNRS UMR7280, 13288 Marseille, France; Médecine Interne, Hôpital de la Timone, Assistance Publique - Hôpitaux de Marseille, Aix-Marseille University, 13005 Marseille, France.
Eric VivierCentre d'Immunologie de Marseille-Luminy, Aix-Marseille University UM2, 13288 Marseille, France; Inserm U1104, 13288 Marseille, France; CNRS UMR7280, 13288 Marseille, France; MI-mAbs Consortium (Aix Marseille University), CIML, 13288 Marseille, France. Electronic address: vivier@ciml.univ-mrs.fr.
DEFI Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural Killer (NK) cells have been shown to exert antiviral and antitumoural activities. Nevertheless most available data are derived from mouse models and functions of these cells in human remain unclear. To evaluate the impact of low circulating NK cell counts and to provide some clues to the role of NK cells in natural conditions, we studied a large cohort of patients with common variable immunodeficiency (CVID) included in a multicenter cohort of patients with primary hypogammaglobulinaemia. Patients were classified into three groups on the basis of their NK cell counts: severe and mild NK cell lymphopenia (<50 and 50-99×10(6)/L respectively), and normal NK cell counts (>100×10(6)/L). Clinical events were analyzed and compared between these three groups of patients. During study period, 457 CVID patients were included: 99 (21.7%) with severe NK cell lymphopenia, 118 (25.8%) with mild NK cell lymphopenia and 240 (52.5%) with normal NK cell counts. Non-infectious complications (57% vs. 36% and 35%), and, particularly, granulomatous complications (25.3% vs. 13.6% and 8.8%), were more frequent in patients with severe NK cell lymphopenia than in other groups. Invasive infections (68.7% vs. 60.2% and 48.8%), including bacteraemia (22.2% vs. 5.9% and 8.3%) and infectious pneumonia (63.6% vs. 59.3% and 44.2%), were also more frequent in this population. However, no difference was observed for viral infections and neoplasms. Low circulating NK cell counts are associated with more severe phenotypes of CVID, which may indicate a protective role of these immune cells against severe bacterial infections and other complications and non-redundant immune functions when the adaptive immune response is not optimal.

Indexed as

AdultCohort StudiesCommon Variable ImmunodeficiencyFemaleFranceHumansKiller Cells, NaturalLymphocyte CountLymphopeniaMaleMiddle AgedCommon variable immunodeficiency (CVID)GranulomaInnate immunityInvasive bacterial infectionsNatural Killer cells (NK cells)Redundancy of immune system

Identifiers

PMID27211564
PMCPMC4856746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.